Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Double Blind Period: MR13A9 0.5 μg/kg Group	0	89
Total, all-cause mortality	Double Blind Period: Placebo Group	1	89
Total, all-cause mortality	Entire Study: MR-MR Group	2	85
Total, all-cause mortality	Entire Study: P-MR Group	2	83
Total, other adverse events	Double Blind Period: MR13A9 0.5 μg/kg Group	27	89
Total, other adverse events	Double Blind Period: Placebo Group	24	89
Total, other adverse events	Entire Study: MR-MR Group	74	85
Total, other adverse events	Entire Study: P-MR Group	74	83
Total, serious adverse events	Double Blind Period: MR13A9 0.5 μg/kg Group	7	89
Total, serious adverse events	Double Blind Period: Placebo Group	10	89
Total, serious adverse events	Entire Study: MR-MR Group	33	85
Total, serious adverse events	Entire Study: P-MR Group	38	83

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04711603/event-totals